A Study of HGS1029 (AEG40826-2HCl) in Subjects With Advanced Solid Tumors
NCT ID: NCT00708006
Last Updated: 2013-11-07
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1
66 participants
INTERVENTIONAL
2008-05-31
2012-01-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
1
HGS1029
HGS1029
Escalating doses by IV (in the vein), on days 1, 8 and 15 of each 28-day cycle. Number of cycles: until disease progression or unacceptable toxicity
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
HGS1029
Escalating doses by IV (in the vein), on days 1, 8 and 15 of each 28-day cycle. Number of cycles: until disease progression or unacceptable toxicity
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Life expectancy of at least 3 months
* Age 18 years or older
* Acceptable liver function
* Acceptable renal function
* Acceptable hematologic status
Exclusion Criteria
* Received non-investigational agent within 3 weeks before enrollment.
* Progressive CNS involvement including the need of corticosteroids
* Pregnant or breast-feeding women
* Active, uncontrolled bacterial, viral, or fungal infections within 2 weeks of Cycle 1 Day 1
* Known HIV infection
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Human Genome Sciences Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Gilles Gallant, B. Pharm.,Ph.D.
Role: STUDY_DIRECTOR
Human Genome Sciences Inc.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Stanford University Dept. of Medicine-Oncology
Stanford, California, United States
University of Colorado Health Sciences Center
Aurora, Colorado, United States
The Sarah Cannon Research Institute
Nashville, Tennessee, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
HGS1029-C1078
Identifier Type: -
Identifier Source: org_study_id